Biodexa Pharmaceuticals
BDRX | NASDAQ
$3.43
-$0.47 (-12.05%)
At close: Oct 30, 2026, 4:00 PM ET
$3.07
-$0.36 (-10.50%)
Pre-market:
Nov 2, 2026, 7:37 AM ET
Market Data
Market Cap $319.9K
Enterprise Value $-2.97M
Beta 1.28
Average Volume 1.26M
Shares Outstanding (Diluted) 18.66M
Shares Change YoY 1037.62%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US59564R8640
Price Performance
Price Change 1M -30.9%
Price Change 3M 141.6%
Price Change 6M 9.9%
Price Change YTD -69.8%
Price Change 1Y -88.9%
Price Change 3Y -99.9%
Price Change 5Y -100.0%
1M CAGR (ann.) -41.3%
1Y CAGR (ann.) -98.6%
5Y CAGR (ann.) -95.8%
All-Time CAGR -86.8%
Valuation
PE Ratio -63.91
Forward PE N/A
PEG Ratio -0.29
Forward PEG 0.64
PS Ratio N/A
Forward PS 83.70
PB Ratio 0.03
P/FCF Ratio -0.03
P/Adj. FCF Ratio -0.03
P/OCF Ratio -6.91
EV/Sales N/A
EV/EBIT 0.31
EV/EBITDA 0.32
EV/FCF 0.43
Earnings Yield -1.6%
FCF Yield -2918.6%
Adj. FCF Yield -2918.6%
Financial Health
Net Cash £3.21M
Total Debt £0
Cash & Short-Term Investments £3.21M
Total Assets £12.64M
Current Ratio 2.41
Quick Ratio 2.41
Debt / Equity Ratio 0.00
Debt / EBITDA -0.00
Debt / FCF -0.00
OCF / Debt N/A
Interest Coverage -364.74
Altman Z-Score -13.57
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin 0.0%
EBITDA Margin 0.0%
Net Profit Margin 0.0%
FCF Margin N/A
Adj. FCF Margin N/A
SBC / Revenue 0.0%
SBC Impact (per share) N/A
Returns
Return on Assets -35.1%
Return on Equity -42.4%
Return on Invested Capital -95.8%
Return on Capital Employed -95.8%
Return on Tangible Assets -66.6%
Historical Growth (CAGR)
Revenue CAGR 3Y -132.9%
Revenue CAGR 5Y -55.8%
Revenue CAGR 10Y -23.0%
EPS CAGR 3Y 149.5%
EPS CAGR 5Y 90.8%
EPS CAGR 10Y 44.3%
FCF CAGR 3Y -2.4%
FCF CAGR 5Y 12.1%
FCF CAGR 10Y 7.6%
Analyst Forecasts
Analyst Rating Hold
Analyst Count 0
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date Apr 23, 2027
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $0.00
Price Target Upside N/A
Cash Flow
Operating Cash Flow £-6.94M
Free Cash Flow £-6.95M
Adj. Free Cash Flow £-6.95M
FCF Per Share -$0.37
OCF Per Share -$0.37
OCF/S Ratio 0.0%
Income Statement
Revenue £0
Gross Profit £-129.29K
Operating Income £-9.47M
EBITDA £-9.34M
Net Income £-4.44M
EPS (Diluted) -$0.04
Revenue / Employee N/A
Profit / Employee $-403.74K
Employees 11
Add to Watchlist
Select watchlists to add or remove BDRX